Glaukos Co. (NYSE:GKOS) Shares Acquired by Rhumbline Advisers

Rhumbline Advisers lifted its position in shares of Glaukos Co. (NYSE:GKOS) by 0.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 141,790 shares of the medical instruments supplier’s stock after purchasing an additional 403 shares during the period. Rhumbline Advisers owned about 0.26% of Glaukos worth $21,260,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Creative Planning increased its stake in shares of Glaukos by 64.1% in the third quarter. Creative Planning now owns 12,643 shares of the medical instruments supplier’s stock worth $1,647,000 after buying an additional 4,937 shares during the last quarter. Assenagon Asset Management S.A. increased its stake in shares of Glaukos by 31.3% in the third quarter. Assenagon Asset Management S.A. now owns 75,798 shares of the medical instruments supplier’s stock worth $9,875,000 after buying an additional 18,067 shares during the last quarter. Values First Advisors Inc. bought a new stake in shares of Glaukos in the third quarter worth $25,000. Louisiana State Employees Retirement System increased its stake in Glaukos by 5.1% during the third quarter. Louisiana State Employees Retirement System now owns 26,600 shares of the medical instruments supplier’s stock valued at $3,465,000 after purchasing an additional 1,300 shares during the last quarter. Finally, State of Alaska Department of Revenue increased its stake in Glaukos by 6.0% during the third quarter. State of Alaska Department of Revenue now owns 31,357 shares of the medical instruments supplier’s stock valued at $4,085,000 after purchasing an additional 1,785 shares during the last quarter. 99.04% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, insider Tomas Navratil sold 3,416 shares of Glaukos stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $147.14, for a total value of $502,630.24. Following the transaction, the insider now owns 72,437 shares of the company’s stock, valued at $10,658,380.18. This trade represents a 4.50 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Gilbert H. Kliman sold 10,000 shares of the firm’s stock in a transaction on Friday, December 20th. The stock was sold at an average price of $150.28, for a total transaction of $1,502,800.00. Following the completion of the sale, the director now owns 32,336 shares in the company, valued at approximately $4,859,454.08. The trade was a 23.62 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 18,744 shares of company stock valued at $2,792,151 over the last 90 days. 6.40% of the stock is currently owned by company insiders.

Glaukos Stock Performance

Shares of GKOS opened at $157.97 on Friday. The company has a 50-day moving average of $153.00 and a two-hundred day moving average of $139.16. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.54 and a quick ratio of 4.71. The stock has a market cap of $8.71 billion, a price-to-earnings ratio of -52.31 and a beta of 1.04. Glaukos Co. has a one year low of $83.90 and a one year high of $163.71.

Glaukos (NYSE:GKOS) last posted its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.02). Glaukos had a negative return on equity of 18.99% and a negative net margin of 42.43%. On average, equities research analysts expect that Glaukos Co. will post -1.89 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the stock. Truist Financial upped their price target on shares of Glaukos from $152.00 to $185.00 and gave the stock a “buy” rating in a research report on Wednesday, December 18th. Morgan Stanley lowered shares of Glaukos from an “equal weight” rating to an “underweight” rating and set a $120.00 price target for the company. in a research report on Monday, December 2nd. Citigroup upgraded shares of Glaukos from a “neutral” rating to a “buy” rating and upped their price target for the stock from $132.00 to $162.00 in a research report on Wednesday, December 11th. Mizuho raised shares of Glaukos from a “neutral” rating to an “outperform” rating and upped their price objective for the stock from $140.00 to $200.00 in a report on Wednesday. Finally, Wells Fargo & Company increased their target price on shares of Glaukos from $145.00 to $153.00 and gave the company an “overweight” rating in a research report on Wednesday, December 11th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $159.42.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.